Logo for CareDx Inc

CareDx Investor Relations Material

Latest events

Logo for CareDx Inc

Q4 2023

CareDx
Logo for CareDx

Q4 2023

28 Feb, 2024
Logo for CareDx

Investor Update

11 Jan, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from CareDx Inc

Access all reports
Segment Data
Access more data
Revenue by
Business area
Testing services
Product services
Patient and digital solutions revenue
Expenses by
Financials
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers UNITY HEART, a precision medicine platform to diagnose the degree of cardiac allograft rejection without the need for a confirmatory endomyocardial biopsy; and UNITY OV, an automated whole blood donor screening system to detect donor-derived cell-free DNA prior to solid organ transplantation and non-invasive as well as categorical monitoring of allograft injury. The company also provides AlloMap heart transplant test that measure mRNA transcripts from 22 genes expressed in immune cells and fibroblasts for personalized patient management; and AlloSure kidney transplant test to measure the amount of a donor specific DNA in a recipient’s bloodstream.